GLP-1 Weight Loss Results: 3.5 Year Clinical Evidence
Long term weight loss outcomes with GLP-1 therapy demonstrate sustained benefits over 3.5 years. This clinical evidence supports ongoing treatment for durable weight management. Patients and clinicians should consider these outcomes when planning…
Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients With Diabetes
The REALISED study shows significant improvements in HbA1c and body weight among Thai patients using oral semaglutide. No severe hypoglycaemia was reported.
New Insights on GLP-1 Receptor Agonist Side Effects from Patient Reports
This analysis focuses on GLP-1 receptor agonist patient-reported side effects gathered from real-world evidence. It highlights emerging safety signals beyond traditional clinical trial data. Clinicians should consider these findings to improve patient…
GLP-1 Receptor Agonist Clinical Evidence: Tirzepatide Real-World Efficacy
Tirzepatide obesity management is supported by real-world clinical evidence demonstrating meaningful weight loss and tolerability. This study highlights tirzepatide’s effectiveness outside controlled trials. It provides valuable insights for clinicians…
GLP-1 Receptor Agonists: Adverse Events and Real-World Efficacy
This article reviews real-world GLP-1 receptor agonist data focusing on adverse events and efficacy. It compares semaglutide and tirzepatide in typical clinical settings. Understanding these differences helps optimize obesity treatment choices.
Understanding GLP-1 Receptor Agonist Treatment Discontinuation
GLP-1 receptor agonist treatment discontinuation often leads to weight regain, highlighting the chronic nature of metabolic disease. Patients frequently restart or switch medications to maintain benefits. Understanding these patterns is crucial for…
GLP-1 Receptor Agonist Real-World Adverse Events
This article reviews real-world adverse events GLP-1 receptor agonists, focusing on semaglutide and tirzepatide. Treatment persistence and gastrointestinal side effects impact clinical outcomes. Understanding these factors helps optimize patient care.
GLP-1 Weight Loss: 4-Year Real-World Evidence
GLP-1 weight loss real-world evidence reveals sustained outcomes over four years with integrated behavioral support. This data informs clinical practice beyond controlled trials. Patients maintain significant weight loss when combining GLP-1 therapy with…
Canadian real-world evidence: observational 24-week outcomes for health care practitioner authorized cannabis.
A large Canadian observational study demonstrates medical cannabis real world effectiveness across chronic pain, anxiety, and sleep disorders over 24 weeks. This real-world evidence provides clinicians with practical outcome expectations for sustained…
Research Study on Maltese Cannabis Users: Insights & Participation
This research study examines the Malta cannabis legalization impact on users following the 2021 law change. It offers valuable real-world evidence on usage patterns and health outcomes. Maltese cannabis users are invited to participate and contribute to…